Cargando…
Minicircle HBV cccDNA with a Gaussia luciferase reporter for investigating HBV cccDNA biology and developing cccDNA-targeting drugs
Chronic Hepatitis B Virus (HBV) infection is generally not curable with current anti-viral drugs. Virus rebounds after stopping treatment from the stable HBV covalently-closed-circular DNA (cccDNA). The development of drugs that directly target cccDNA is hampered by the lack of robust HBV cccDNA mod...
Autores principales: | Li, Feng, Cheng, Liang, Murphy, Christopher M., Reszka-Blanco, Natalia J., Wu, Yaxu, Chi, Liqun, Hu, Jianming, Su, Lishan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5098228/ https://www.ncbi.nlm.nih.gov/pubmed/27819342 http://dx.doi.org/10.1038/srep36483 |
Ejemplares similares
-
The Role of cccDNA in HBV Maintenance
por: Allweiss, Lena, et al.
Publicado: (2017) -
HBV cccDNA: The Stumbling Block for Treatment of HBV Infection
por: Liu, Shousheng, et al.
Publicado: (2019) -
Mapping the Interactions of HBV cccDNA with Host Factors
por: Mohd-Ismail, Nur K., et al.
Publicado: (2019) -
Gene Editing Technologies to Target HBV cccDNA
por: Martinez, Maria Guadalupe, et al.
Publicado: (2022) -
HBV cccDNA and Its Potential as a Therapeutic Target
por: Zhu, Anjing, et al.
Publicado: (2019)